Price movement over the last 24 hours
AGCO Corporation vs Davita Inc — how do they compare? AGCO Corporation trades at $112.73 (market cap $8.24B), while Davita Inc trades at $231.41 (market cap $15.04B). The key difference: Davita Inc is the larger of the two by market cap, and AGCO Corporation pays a 1.05% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| AGCO | DVA | |
|---|---|---|
Market Cap | $8.24B | $15.04B |
Sector | Industrials | Health |
52-Week High | $140.49 | $235.71 |
52-Week Low | $100.14 | $103.87 |
Enterprise Value | $10.41B | $27.59B |
Dividend Yield | 1.05% | — |
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $113.75, down 2.35% today, with a neutral technical signal and bullish moving averages. The company shows solid fundamentals with a P/E of 11.41 and net income margin of 7.43%, supported by three consecutive earnings beats. Recent news highlights marketing initiatives and fuel efficiency advancements, while cash flow improved to $249.10M in 2025 from negative levels in prior years.
The outlook remains positive with a consensus price target of $147.50, implying 30% upside, though risks include agricultural sector volatility and debt levels. Earnings momentum and valuation discounts present opportunities, but investor sentiment is balanced with equal buy/hold ratings from analysts.
DaVita (DVA) trades at $234.31, showing modest daily decline but maintaining strong momentum near 52-week highs. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth continues with $13.64B in 2025, while net margins of 5.65% reflect steady profitability. Recent news highlights DVA's expansion in kidney care delivery and AI-driven scheduling improvements, positioning the company for continued growth in specialized healthcare services.
Investment outlook remains positive with analyst consensus favoring Buy ratings (39%) and price targets averaging $211. Key opportunities include expanding kidney care services and operational efficiencies, while risks involve high debt levels (65.55% debt-to-asset ratio) and healthcare regulatory pressures. Current valuation metrics (P/E 22.71, P/S 1.24) appear reasonable given growth prospects, though the stock trades above consensus targets.
Trailing returns across standard periods
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →